Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints.
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
FRANKFURT, Feb 19 (Reuters) - The European Union's healthcare regulator will this week review the use of Eli Lilly's LLY.N approved Mounjaro drug against diabetes and obesity when prefilled in a multi ...
Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply as it ...